Vor Biopharma Inc is a biotechnology company based in Cambridge, MA that is dedicated to revolutionizing the treatment of blood cancers. Their innovative approach involves shielding healthy cells from targeted therapies, allowing these therapies to focus their effects on cancer cells, potentially leading to a cure. Through their proprietary platform, which combines genome engineering, Hematopoietic Stem Cell (HSC) biology, and CAR-T cells, Vor Biopharma aims to delay relapse post-transplant and provide new treatment options for patients with AML and other blood cancers.
Vor Biopharma's novel approach to blood cancer treatment is based on the latest scientific advancements in cell and genome engineering. By developing treatment-resistant HSCs and genetically editing them to be resistant to targeted therapies, Vor Biopharma aims to protect healthy blood cells and selectively attack cancer cells. Their ongoing clinical trials and research efforts demonstrate their commitment to transforming the field of blood cancer treatment and potentially offering curative options for patients.
Generated from the website